In a study published July 14 in the New England Journal of Medicine, researchers report on the results of the first COVID-19 vaccine to be tested in humans. The study involved 45 healthy volunteers were involved, it was designed to test the safety of the vaccine, but the results provide initial evidence of its effectiveness. Moderna Therapeutics, the Mass.-based biotech company that developed the vaccine along with researchers from the National Institute of Allergy and Infectious Diseases, first reported the results in a press release dated May 18 Des NEJM paper formally describing these results. The 45 participants aged between 18 and 55 years, were either enrolled in the Kaiser Permanente Health Research Institute in Seattle Washington or at the Emory University in Atlanta; The first volunteer was vaccinated on 16 March, just two months after the genetic sequence of the SARS-CoV-2 was released. All subjects received one of three levels of vaccine doses that have been given separately in two injections in the course of a month. There were no serious side effects associated with the vaccine on each dosage level, although more than half of the study participants who received the vaccine, experienced smaller events, such as fatigue, headache, chills and pain injection site. All participants have produced antibodies against SARS-CoV-2, the virus that causes COVID-19 And when the researchers tested these antibodies against a laboratory version of SARS-CoV-2, have found these antibodies effective virus such as antibodies They neutralized by people who were naturally infected with SARS-CoV-2 and recovered. They also tested the stretch by a small group of study participants of antibodies against the real samples of SARS-CoV-2 and find their ability to neutralize the virus at least that was equivalent in people who had recovered from the infection. In both cases, the reactions were stronger, expect the experts, after the second shot. “We have seen strong reactions after the second vaccination,” said Dr. Lisa Jackson, lead author of the NEJM study. “It seems that two doses are needed, this is what you would expect from this type of vaccine, and a vaccine against a new virus that has not been in the population. The needs of the immune system to be the first dose then reacts set more on second “. Preventive treatment is based on a new technology that has not yet produced a vaccine approved for an infectious disease. Using mRNA-2 virus from SARS-CoV, the plot uses the body’s own cells to mimic the process to produce viral proteins from natural infection, which are recognized by the immune system. How long does the immune response induced by the vaccine lasts for protection against COVID-19 it is not yet clear; The 45 participants in this study will be monitored for a year to find out. Meanwhile, plans Modern two investigational vaccine trials, 300 people will cover half placed in a placebo group already his. The study will continue to evaluate the safety and efficacy of the vaccine, as well as reduce the right dose for the final phase of testing. the urgent need for a vaccine, the Food and Drug Administration has already given that the phase 3 study involved 30,000 people who compare the effectiveness of the actual vaccine against a placebo.